Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesA Novel Mechanism for the Treatment of Angina, Arrhythmias, and Diastolic Dysfunction: Inhibition of Late INa Using Ranolazine
Journal of Cardiovascular Pharmacology, 08/26/09
Maier LS – In the recent years, increased late INa was suggested to contribute to this phenomenon by elevating intracellular Na concentration with subsequent rise in diastolic Ca levels by means of the sarcolemmal Na–Ca exchange system. Ranolazine, a specific inhibitor of late INa, reduces Na influx and hence ameliorates disturbed Na and Ca homeostasis. This is associated with a symptomatic improvement of angina in patients unlike other antianginal drugs without affecting heart rate or systemic blood pressure as shown in placebo–controlled studies. Therefore, ranolazine is a useful new option for patients with chronic stable angina not only as an add–on therapy. New clinical and experimental studies even point to potential antiarrhythmic effects, beneficial effects in diastolic heart failure, and under hyperglycemic conditions.
Related Articles
Use-dependent block of cardiac late Na+ current by ranolazine
Heart Rhythm, 11/06/09
Relevance Score: 87%
Ranolazine, an Antianginal Agent, Markedly Reduces Ventricular Arrhythmias Induced by Ischemia and Iscehmia-Reperfusion
Heart And Circulatory Physiology, 10/02/09
Relevance Score: 84%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences
Vascular Health and Risk Management, 11/30/09
Vernakalant hydrochloride for the treatment of atrial fibrillation
Expert Opinion on Investigational Drugs, 11/30/09
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/30/09
Today in Coronary Artery Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
The innateness of coronary artery: Vasa vasorum
Medical Hypotheses, 11/30/09
Relation of left ventricular mass and concentric remodeling to extent of coronary artery disease by computed tomography in patients without left ventricular hypertrophy: ROMICAT study
Journal of Hypertension, 11/30/09
What is the clinical usefulness of the metabolic syndrome? The Casale Monferrato study
Journal of Hypertension, 11/30/09
Today in Myocardium/Pericardium...keeping you current
Receive free subspecialty "5-minute updates" via email
Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality and Outcomes
JAMA, 11/25/09
Mode of arrival does not predict myocardial infarction in patients who present to the ED with chest pain
International Journal of Emergency Medicine, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor